| Issue |
Section |
Title |
File |
| Vol 16, No 1S (2009) |
Articles |
ANTIANGIOGENNYE PREPARATY V LEChENII RAKA MOLOChNOY ZhELEZY |
|
| Vol 19, No 18 (2012) |
Articles |
A new approach to the overcoming resistance to hormone therapy of breast cancer |
|
| Vol 20, No 17 (2013) |
Articles |
Znachenie molekulyarnykh markerov pri vybore neoad\"yuvantnoy khimioterapii mestno-rasprostranennogo raka molochnoy zhelezy |
|
| Vol 23, No 8 (2016) |
Articles |
NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER |
|
| Vol 23, No 17 (2016) |
Articles |
TAXANES IN THE TREATMENT OF BREAST CANCER |
|
| Vol 24, No 17 (2017) |
Articles |
New possibilities of the treatment of breast cancer: microtubule inhibitors |
|
| Vol 25, No 7 (2018) |
Articles |
GONADOTROPIN-RELEASING HORMONE AGONISTS-INDUCED OVARIAN SUPPRESSION IN EARLY BREAST CANCER |
|
| Vol 25, No 12 (2018) |
Articles |
Ways to improve efficiency of endocrino-therapy of breast cancer: new targeted cells, new therapeutic opportunities |
|
| Vol 27, No 7 (2020) |
Articles |
Alpelisib for the treatment of HR+HER2-metastatic breast cancer in patients with the PIK3CA mutation: results of the SOLAR-1 study |
|
| Vol 27, No 7 (2020) |
Articles |
Treatment of residual breast cancer |
|
| Vol 27, No 7 (2020) |
Articles |
Abemacyclib - new options for the treatment of hormone-positive metastatic breast cancer with CDK4/6 inhibitors |
|
| Vol 29, No 7 (2022) |
Articles |
Predictive and prognostic role of tumor-infiltrating lymphocytes (TILs) in early triple-negative breast cancer |
|
| Vol 29, No 7 (2022) |
Articles |
Treatment of HER2-positive early (minimal) breast cancer |
|
| Vol 29, No 11/12 (2022) |
Articles |
The role of alpelisib in the treatment of PIK3CA - a mutated breast cancer |
|
| Vol 29, No 11/12 (2022) |
Articles |
Ixabepilone in the treatment of breast cancer |
|
